- Monday, 3 March 2014
- US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the BYDUREON® Pen
- Tuesday, 25 February 2014
- US FDA approves orphan drug MYALEPT™ (metreleptin for injection) AstraZeneca today announced the US Food and Drug Administration (FDA) approved orphan drug MYALEPT™ (metreleptin for injection), which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patients with congenital or acquired generalised lipodystrophy. MYALEPT, a recombinant analogue (laboratory-created form) of human leptin, is the first and only treatment approved by the FDA for these patients.
- Thursday, 6 February 2014
- AstraZeneca PLC fourth quarter and full year results 2013 Pascal Soriot, Chief Executive Officer, commenting on the results, said: "As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands. In the near term these headwinds will remain challenging, however I am confident that we can return to growth faster than anticipated and expect our 2017 revenues will be broadly in line with 2013. I’m pleased with the momentum we have built in 2013 against our strategic priorities, in particular our objective of achieving scientific leadership. We continue to focus our organisation on the areas that will drive growth, redeploying our resources to fund the promising late-stage pipeline, which nearly doubled in size over the last 12 months. The acquisition of Bristol-Myers Squibb’s share of our diabetes alliance strengthens our position in this important area and I am delighted that the business integration is progressing with such pace. We extend a warm welcome to our new colleagues who will help us maximise the potential of our diabetes portfolio.”
- Monday, 3 February 2014
- AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance AstraZeneca today announced that it has completed, on 1 February 2014, its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
- Wednesday, 22 January 2014
- XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (EU).
- Tuesday, 14 January 2014
- AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth Pascal Soriot, Chief Executive Officer, AstraZeneca will today present at the JP Morgan Healthcare Conference in San Francisco, CA at 4:30 pm Pacific time. At the conference, Pascal Soriot will provide an update on the company’s development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.
- Monday, 13 January 2014
- US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes In clinical trials, new once-daily FARXIGA, in addition to diet and exercise, improved glycaemic control by removing glucose from the body
- Wednesday, 8 January 2014
- AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin) AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGA™ (dapagliflozin).
- Wednesday, 8 January 2014
- MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
- Thursday, 26 December 2013
- AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR® AstraZeneca and Shionogi & Co. Ltd. today announced the full resolution of arbitration proceedings related to the treatment of certain excise taxes and other specific items in the calculation of royalties on CRESTOR® sales. In addition, AstraZeneca and Shionogi & Co. Ltd. announced the extension of the global licence agreement for CRESTOR® and the modification of the royalty structure, effective 1 January 2014.
AZ & Korea Health Industry Development Institute signing agreement for new oncology research programme http://t.co/JUXvPHLRlS7 Mar
Yang: “We have strong belief in the translational & clinical research capability of Korean oncology scientists” http://t.co/cmH6sNAGbW7 Mar
AstraZeneca & Korea Health Industry Development Institute to establish oncology research programme http://t.co/cmH6sNAGbW7 Mar